Unresectable Melanoma Clinical Trials

69 clinical trials for Unresectable Melanoma across international registries, including 11 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study — RECRUITING · PHASE2
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer — RECRUITING · PHASE1
• Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma — RECRUITING · PHASE2
• Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. — RECRUITING · PHASE3
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel — RECRUITING · PHASE1
• A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer — RECRUITING · PHASE1
• Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma — RECRUITING · PHASE1
• A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma — RECRUITING · PHASE2
• Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients — RECRUITING
• Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma — RECRUITING · PHASE2
• A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India — NOT_YET_RECRUITING · PHASE4
• Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma — ACTIVE_NOT_RECRUITING · PHASE1
• Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma — TERMINATED · PHASE2
• Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread — ACTIVE_NOT_RECRUITING · PHASE2
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma — ACTIVE_NOT_RECRUITING · PHASE3
• Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery — ACTIVE_NOT_RECRUITING · PHASE2
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial — ACTIVE_NOT_RECRUITING · PHASE2
• Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery — ACTIVE_NOT_RECRUITING · PHASE1
• In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma — TERMINATED · PHASE2
• Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma — COMPLETED · PHASE2
• Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release — OTHER
• Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma — COMPLETED · PHASE1
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma — COMPLETED · PHASE1
• Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy — ACTIVE_NOT_RECRUITING · PHASE2
• Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma — TERMINATED · PHASE1
• A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment — COMPLETED · PHASE2
• STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma — WITHDRAWN · PHASE1
• Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma — TERMINATED · PHASE1
• Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery — COMPLETED · PHASE2
• A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) — ACTIVE_NOT_RECRUITING · PHASE3
• Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung — WITHDRAWN · PHASE1
• Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma — COMPLETED · PHASE1
• Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma — COMPLETED · PHASE2
• CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma — TERMINATED · PHASE2
• Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies — TERMINATED · PHASE1
• Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy — ACTIVE_NOT_RECRUITING · PHASE2
• A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma — TERMINATED · PHASE1
• Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer — COMPLETED · PHASE1
• Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma — COMPLETED · PHASE2

Refine this search